Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c, Revenues Beat

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

March 12, 2020 4:05 PM EDT

Reported Positive Data from Phase 1/2a Clinical Trial of OpRegen®; All Cohort 4 Patients Have Improved Visual Acuity at Twelve Months or as of Last Visit (Gained Between 8-25 Readable Letters) Entered into Agreements with Three Companies for Certain IP and Assets Provided Positive Clinical Update from SCiStar Trial of OPC1 for Spinal Cord Injury Strengthened Extensive IP Portfolio with the Issuance of 3 New U.S. Patents Awarded $3.2 Million in Grants from Israel Innovation Authority and NIH Extended Anticipated Cash Runway by Implementing Cost Savings Initiatives and... More